GlassScriptPhysician profile
John Burton Calhoun
NPI 1770845141
$2,995.22
in general payments reported to CMS, 2019-2025
29 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $512 · 2020: $426 · 2021: $629 · 2022: $581 · 2023: $282 · 2024: $206 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $848.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $582.85 | 2019-2023 | Spravato |
| Abbvie INC. | $458.68 | 2020-2024 | Qulipta, Vraylar, Linzess |
| Novo Nordisk INC | $300.37 | 2019-2022 | |
| Glaxosmithkline, LLC. | $214.85 | 2020-2025 | Trelegy Ellipta |
| Nevro Corp. | $197.27 | 2021-2023 | Senza |
| Amarin Pharma, INC. | $148.97 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $115.22 | 2019-2022 | |
| Abiomed | $114.93 | 2025 | |
| Abbott Laboratories | $109.52 | 2021-2023 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $97.26 | 2019-2025 | Airsupra |
| Amgen INC. | $97.10 | 2024-2025 | Evenity, Repatha, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.20 | 2019 | |
| Allergan, INC. | $61.10 | 2019-2020 | |
| Medtronic, INC. | $59.46 | 2025 | Symplicity G3 |
| Pfizer INC. | $57.91 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $45.09 | 2020-2022 | |
| Dexcom, INC. | $44.13 | 2024-2025 | Dexcom G6 Transmitter |
| Shire North American Group INC | $38.32 | 2019 | |
| Sanofi-Aventis U.S. LLC | $36.02 | 2020 | |
| Inspire Medical Systems, INC. | $18.71 | 2025 | Inspire |
| Xeris Pharmaceuticals, INC. | $18.40 | 2023 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $16.94 | 2021 | |
| Astellas Pharma US INC | $15.83 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $14.14 | 2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $12.50 | 2019 | |
| Horizon Therapeutics Plc | $12.13 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.11 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.31 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Calhoun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.